Adjuvant tamoxifen influences the lipid profile in breast cancer patients

Breast Care

Volumn 9, Issue 1, 2014, Pages 35-39

  Lin, Che ^a,b,c   Chen, Li Sheng ^d,e   Kuo, Shou Jen ^b,f   Chen, Dar Ren ^a,b,f  

^a Department of Research ^*  (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Lipid profile; Low density lipoprotein cholesterol; Metabolism; Tamoxifen; Total cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; LIPID; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LYMPH NODE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; PHYSICIAN; TAIWANESE;

EID: 84897050246     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000358752     Document Type: Article

References (26)

1. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, Delisi C, Bhanot G: Breast cancer stratification from analysis of micro-array data of micro-dissected specimens. Genome Inform 2007;18:130-140.
2. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid receptor-negative basal- like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008;105:5774-5779.
3. Verma S, Tabb MM, Blumberg B: Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer 2009;9:3.
4. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM: Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009;115:325-333.
5. Hernandez RK, Sorensen HT, Jacobsen J, Pedersen L, Lash TL: Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol Biomarkers Prev 2008;17:2509-2511.
6. Elefsiniotis IS, Pantazis KD, Ilias A, Pallis L, Mariolis A, Glynou I, Kada H, Moulakakis A: Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: The role of glucose intolerance. Eur J Gastroenterol Hepatol 2004;16:593-598.
7. Esteva FJ, Hortobagyi GN: Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 2006;15:301-312.
8. Farrell GC: Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194.
9. Hozumi Y, Kawano M, Saito T, Miyata M: Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-1635.
10. Lewis S: Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007;153:182-188.
11. Liu CL, Yang TL: Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 2003;79:11-16.
12. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005;93:61-66.
13. McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I: Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004; 34:67-79.
14. Nowak AK, Stockler MR, Chow PK, Findlay M: Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer 2005;103: 1408-1414.
15. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL: Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007;97:582-588.
16. Yuvaraj S, Premkumar VG, Shanthi P, Vijayasarathy K, Gangadaran SG, Sachdanandam P: Effect of coenzyme Q(10), riboflavin and niacin on tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. Breast Cancer Res Treat 2009;114:377-384.
17. Montagnani A, Gonnelli S, Cadirni A, Caffarelli C, Del Santo K, Pieropan C, Campagna MS, Montomoli M, Petrioli R, Nuti R: The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med 2008;19:592-597.
18. Chang NW, Chen FN, Wu CT, Lin CF, Chen DR: Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients. Clin Chim Acta 2009;401:144-147.
19. Liberopoulos E, Karabina SA, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, Elisaf M: Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 2002;62:115-120.
20. Cho SE, Nam JW, Hong KS: Performance evaluation of the Hitachi 7600-110 chemistry autoanalyzer. Korean J Clin Pathol 2001;21:331-337.
21. Tan SH, Lee SC, Goh BC, Wong J: Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008;14:8027-8041.
22. Rodriguez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679-1691.
23. Lee MM, Chang IY, Horng CF, Chang JS, Cheng SH, Huang A: Breast cancer and dietary factors in Taiwanese women. Cancer Causes Control 2005; 16:929-937.
24. Norman AW, Mizwicki MT, Norman DP: Steroidhormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004;3:27-41.
25. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR: Muc1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009;106:5837-5841.
26. Chajes V, Lanson M, Fetissof F, Lhuillery C, Bougnoux P: Membrane fatty acids of breast carcinoma: contribution of host fatty acids and tumor properties. Int J Cancer 1995;63:169-175.